Equities research analysts expect that Celldex Therapeutics, Inc. (NASDAQ:CLDX) will post earnings of ($0.26) per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Celldex Therapeutics’ earnings. The highest EPS estimate is ($0.23) and the lowest is ($0.27). Celldex Therapeutics posted earnings per share of ($0.32) in the same quarter last year, which suggests a positive year-over-year growth rate of 18.8%. The business is expected to announce its next earnings report on Monday, August 14th.
According to Zacks, analysts expect that Celldex Therapeutics will report full-year earnings of ($1.10) per share for the current year, with EPS estimates ranging from ($1.23) to ($0.97). For the next year, analysts anticipate that the business will post earnings of ($1.00) per share, with EPS estimates ranging from ($1.19) to ($0.82). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Celldex Therapeutics.
Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.28) EPS for the quarter, meeting analysts’ consensus estimates of ($0.28). The company had revenue of $1.53 million for the quarter, compared to analyst estimates of $0.57 million. Celldex Therapeutics had a negative net margin of 1,825.82% and a negative return on equity of 53.10%.
Several analysts have weighed in on CLDX shares. Aegis reissued a “buy” rating on shares of Celldex Therapeutics in a report on Tuesday, March 21st. ValuEngine cut Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 3rd. Jefferies Group LLC reaffirmed a “hold” rating and issued a $3.50 price target (down from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, May 11th. Zacks Investment Research raised Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a research note on Wednesday, May 31st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, March 15th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. Celldex Therapeutics has a consensus rating of “Buy” and an average target price of $6.86.
Celldex Therapeutics (NASDAQ:CLDX) traded up 0.80% on Tuesday, reaching $2.52. 1,069,055 shares of the company’s stock were exchanged. The firm’s market capitalization is $315.26 million. Celldex Therapeutics has a 1-year low of $2.20 and a 1-year high of $5.02. The stock’s 50 day moving average price is $2.72 and its 200 day moving average price is $3.26.
COPYRIGHT VIOLATION NOTICE: “Celldex Therapeutics, Inc. (NASDAQ:CLDX) Expected to Post Earnings of -$0.26 Per Share” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/07/18/celldex-therapeutics-inc-nasdaqcldx-expected-to-post-earnings-of-0-26-per-share-updated.html.
Several hedge funds have recently made changes to their positions in the stock. FMR LLC raised its stake in shares of Celldex Therapeutics by 40.3% in the fourth quarter. FMR LLC now owns 19,327,111 shares of the biopharmaceutical company’s stock worth $68,418,000 after buying an additional 5,555,595 shares during the last quarter. Meditor Group Ltd purchased a new stake in shares of Celldex Therapeutics during the first quarter worth approximately $14,966,000. Vanguard Group Inc. raised its stake in shares of Celldex Therapeutics by 16.4% in the first quarter. Vanguard Group Inc. now owns 9,066,763 shares of the biopharmaceutical company’s stock worth $32,731,000 after buying an additional 1,278,206 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Celldex Therapeutics by 42.4% in the first quarter. Renaissance Technologies LLC now owns 1,707,927 shares of the biopharmaceutical company’s stock worth $6,166,000 after buying an additional 508,217 shares during the last quarter. Finally, State of Wisconsin Investment Board raised its stake in shares of Celldex Therapeutics by 206.3% in the first quarter. State of Wisconsin Investment Board now owns 750,000 shares of the biopharmaceutical company’s stock worth $2,708,000 after buying an additional 505,138 shares during the last quarter. 64.66% of the stock is currently owned by hedge funds and other institutional investors.
About Celldex Therapeutics
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.